Survival data for 648 patients with osteosarcoma treated at one institution

Clinical Orthopaedics and Related Research

Volumn 429, Issue , 2004, Pages 286-291

  Mankin, Henry J ^a,b   Hornicek, Francis J ^a   Rosenberg, Andrew E ^a   Harmon, David C ^a   Gebhardt, Mark C ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FOLINATE CALCIUM; IFOSFAMIDE; METHOTREXATE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CORRELATION ANALYSIS; DRUG USE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; METASTASIS; OSTEOSARCOMA; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; SEX RATIO; SURVIVAL TIME; TUMOR LOCALIZATION; TUMOR VOLUME;

EID: 9644289260     PISSN: 0009921X     EISSN: 15281132     Source Type: Journal    
DOI: 10.1097/01.blo.0000145991.65770.e6     Document Type: Article

References (82)

1. Anbari KK, Ierardi-Curto LA, Silber JS, et al: Two primary osteosarcomas in a patient with Rothmund-Thomson syndrome. Clin Orthop 378:213-223, 2000.
2. Bacci G, Ferrari S, Longhi A, et al: Relationship between dose-intensity of treatment and outcome for patients with osteosarcoma of the extremity treated with neoadjuvant chemotherapy. Oncol Rep 8:883-888, 2001.
3. Bacci G, Picci P, Ruggieri P, et al: Primary chemotherapy and delayed surgery (neoadjuvant chemotherapy) for osteosarcoma of the extremities: The Istituto Rizzoli experience in 127 patients treated preoperatively with intravenous methotrexate (high versus moderate doses) and intraarterial cisplatin. Cancer 65:2539-2553, 1990.
4. Bailar III JC, Mosteller F: Guidelines for statistical reporting in articles for medical journals: Amplifications and explanations. Ann Intern Med 108:266-273, 1988.
5. Baum ES, Gaynon P, Greenberg L, Krivit W, Hammond D: Phase II study of cis-dichlorodiammineplatinum(II) in childhood osteosarcoma. Children's Cancer Study Group Report. Cancer Treat Rep 63:1621-1627, 1979.
6. Berend KR, Pietrobon R, Moore JO, et al: Adjuvant chemotherapy for osteosarcoma may not increase survival after neoadjuvant chemotherapy and surgical resection. J Surg Oncol 78:162-170, 2001.
7. Bielack SS, Kempf-Bielack B, Delling G, et al: Prognostic factors in high-grade osteosarcoma of the extremities or trunk: An analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 20:776-790, 2002.
8. Brosjo O: Surgical procedure and local recurrence in 223 patients treated 1982-1997 according to osteosarcoma chemotherapy protocols: The Scandinavian Sarcoma Group experience. Acta Orthop Scand Suppl 285:58-61, 1999.
9. Campanacci M: Bone and Soft Tissue Tumors. New York, Springer 463-516, 1999.
10. Campanacci M, Cervellati C: Osteosarcoma: A review of 345 cases. Ital J Orthop Traumatol 1:5-22, 1975.
11. Carsi B, Rock MG: Primary osteosarcoma in adults older than 40 years. Clin Orthop 397:53-61, 2002.
12. Coley BL, Harrold Jr CC: An analysis of fifty-nine cases of osteogenic sarcoma with survival for five years or more. J Bone Joint Surg 32A:307-310, 1950.
13. Coley WB: The treatment of malignant tumors by repeated inoculations of erysipelas: With a report of ten original cases. Am J Med Sci 105:487-511, 1893.
14. Cortes EP, Holland JF, Wang JJ, Sinks LF: Doxorubicin in disseminated osteosarcoma. JAMA 221:1132-1138, 1972.
15. Coventry MB, Dahlin DC: Osteogenic sarcoma: A critical analysis of 430 cases. J Bone Joint Surg 39A:741-758, 1957.
16. Cox DR: Regression models and life tables. J R Stat Soc 34:187-220, 1972.
17. Cumin I, Cohen JY, David A, et al: Rothmund-Thomson syndrome and osteosarcoma. Med Pediatr Oncol 26:414-416, 1996.
18. Dahlin DC: Bone Tumors. Ed 2. Springfield, IL, CC Thomas 156-185, 1967.
19. Dahlin DC, Coventry MB: Osteogenic sarcoma: A study of six hundred cases. J Bone Joint Surg 49A:101-110, 1967.
20. Damadian R, Zaner K, Hor D, Dimaio T: Human tumors by NMR. Physiol Chem Phys 5:381-402, 1973.
21. Dick DC, Morley WN, Watson KT: Rothmund-Thompson syndrome and osteogenic sarcoma. Clin Exp Dermatol 7:119-123, 1983.
22. Dickens DS, Kozielski R, Leavey PJ, Timmons C, Cripe TP: Cyclooxygenase-2 expression does not correlate with outcome in osteosarcoma or rhabdomyosarcoma. J Pediatr Hematol Oncol 25: 282-285, 2003.
23. Dorfman HD, Czerniak B: Bone Tumors. St Louis, Mosby 128-252, 1988.
24. Draper GJ, Sanders BM, Kingston JE: Second primary neoplasms in patients with retinoblastoma. Br J Cancer 53:661-671, 1986.
25. Dupuytren G: Tumors of bone. Bull Ecole Med de Paris 2:13-24, 1805.
26. Enneking WF: A System for Evaluation of the Surgical Management of Musculoskeletal Tumors. In Enneking WF (ed). Limb Salvage in Musculoskeletal Oncology. New York, Churchill Livingstone 145-150, 1987.
27. Enneking WF, Spanier SS, Goodman MA: Current concepts review: The surgical staging of musculoskeletal sarcoma. J Bone Joint Surg 62A:1027-1030, 1980.
28. Fahey M, Spanier SS, Van der Griend RA: Osteosarcoma of the pelvis. J Bone Joint Surg 74A:321-330, 1992.
29. Ferrari S, Bacci G, Picci P, et al: Long term follow-up and post-relapse survival in patients with non-metastatic osteosarcoma of the extremity treated with neoadjuvant chemotherapy. Ann Oncol 8:765-771, 1997.
30. Ferrari S, Briccoli A, Mercuri M, et al: Postrelapse survival in osteosarcoma of the extremities: Prognostic values for long-term survival. Clin Oncol 21:710-715, 2003.
31. Frassica FJ, Sim SH, Frassica DA, Wold LE: Survival and management considerations in post irradiation osteosarcoma and Paget's osteosarcoma. Clin Orthop 270:120-127, 1991.
32. Goidanich IF, Battaglia L, Lenzi L, Silva E: Osteogenic sarcoma: Analysis of factors influencing prognosis in 100 cases. Clin Orthop 48:209-222, 1966.
33. Gokgoz N, Wunder JS, Mousses S, et al: Comparison of p53 mutations in patients with localized osteosarcoma and metastatic osteosarcoma. Cancer 92:2181-2189, 2001.
34. Goorin AM, Abelson HT, Frei E: Osteosarcoma fifteen years later. N Engl J Med 313:1637-1643, 1985.
35. Gorlick R, Huvos AG, Heller G, et al: Expression of HER2/erbB-2 correlates with survival in osteosarcoma. J Clin Oncol 17:2781-2788, 1999.
36. Gross SW: Sarcoma of the long bones: Based on the study of one hundred and sixty-five cases. Am J Med Sci 78:2-57, 1879.
37. Hatcher CH: The development of sarcoma in bone subjected to roentgen or radium irradiation. J Bone Joint Surg 27:179-195, 1945.
38. Hauben EI, Weeden S, Pringle J, Van Marck EA, Hogendoorn PC: Does the histological subtype of high-grade central osteosarcoma influence the response to treatment with chemotherapy and does it affect overall survival? A study on 570 patients of two consecutive trials of the European Osteosarcoma Intergroup. Eur J Cancer 38: 1218-1225, 2002.
39. Homicek FJ, Gebhardt MC, Wolfe MW, et al: P-glycoprotein levels predict poor outcome in patients with osteosarcoma. Clin Orthop 373:11-17, 2000.
40. Hounsfield GN: Computerized transverse axial scanning (tomography). Br J Radiol 46:1016-1022, 1973.
41. Jaffe HL: Osteogenic sarcoma of bone. Clin Orthop 7:27-40, 1956.
42. Jaffe N, Farber S, Traggis D, et al: Favorable response of osteogenic sarcoma to high dose methotrexate with citrovorum rescue and radiation therapy. Cancer 31:1367-1373, 1973.
43. Kakar S, Mihalov M, Chachalani NA, Ghosh L, Johnstone H: Correlation of c-fos, p53 and PCNA expression with treatment outcome in osteosarcoma. J Surg Oncol 73:125-126, 2000.
44. Kaplan E, Meier P: Non-parametric estimation for incomplete observations. J Am Stat Assoc 53:457-481, 1958.
45. Kawaguchi K, Oda Y, Sakamoto A, et al: Molecular analysis of p53, MDM2 and H-ras genes in osteosarcoma and malignant fibrous histiocytoma of bone in patients older than 40 years. Mod Pathol 15:878-888, 2002.
46. Lewis IJ, Weeden S, Machin D, Stark D, Craft AW: Received doses and dose intensity of chemotherapy and outcome in non-metastatic extremity osteosarcoma: European Osteosarcoma Intergroup. J Clin Oncol 18:4028-4037, 2000.
47. Li FP, Fraumeni Jr JF, Mulvihill JJ, et al: A cancer family syndrome in twenty-four kindreds. Cancer Res 48:5358-5363, 1988.
48. Lichtenstein L: Bone Tumors. St Louis, CV Mosby Company 191-214, 1959.
49. Lindner NJ, Ramm O, Hillmann A, et al: Limb salvage and outcome of osteosarcoma: The University of Muenster experience. Clin Orthop 358:83-89, 1999.
50. Link PM, Goorin AM, Horowitz M, et al: Adjuvant chemotherapy of high grade osteosarcoma of the extremity: Updated results of the multi-international osteosarcoma study. Clin Orthop 270:8-14, 1991.
51. Maitra A, Wanzer D, Weinberg AG, Ashfaq R: Amplification of the HER-2/neu oncogene is uncommon in pediatric osteosarcomas. Cancer 92:677-683, 2001.
52. Malmud LS, Charkes ND: Bone scanning: Principles, technique and interpretation. Clin Orthop 107:112-122, 1975.
53. Mankin HJ, Gebhardt MC, Springfield DS, et al: Flow cytometric studies of human osteosarcoma. Clin Orthop 270:169-180, 1991.
54. Marsden FW, Stephens FO, McCarthy SW, Ferrari AM: IIB osteosarcoma: Current management, local control and survival statistics- the Australian experience. Clin Orthop 270:113-119, 1991.
55. Mervak TR, Unni KK, Pritchard DJ, McLeod RA: Telangiectatic osteosarcoma. Clin Orthop 270:135-139, 1991.
56. Ogihara Y, Sudo A, Fujinami S, Sato K, Miura T: Current management, local management and survival statistics of high grade osteosarcoma: Experience in Japan. Clin Orthop 270:72-78, 1991.
57. O'Hara JM, Hutter RV, Foote Jr FW, Miller T, Woodard HQ: An analysis of 30 patients surviving longer than ten years after treatment for osteogenic sarcoma. J Bone Joint Surg 50A:335-354, 1968.
58. Pakos EE, Ioannidis JP: The association of P-glycoprotein with response to chemotherapy and clinical outcome in patients with osteosarcoma: A meta-analysis. Cancer 98:581-589, 2003.
59. Park YB, Kim HS, Oh JH, Lee SH: The co-expression of p53 protein and p-glycoprotein is correlated to a poor prognosis in osteosarcoma. Int Orthop 24:307-310, 2001.
60. Potepan P, Luksch R, Sozzi G, et al: Multifocal osteosarcoma as second tumor after childhood retinoblastoma. Skeletal Radiol 28:415-421, 1999.
61. Pujol LA, Erickson RP, Heidenreich RA, Cunniff C: Variable presentation of Rothmund-Thomson syndrome. Am J Med Genet 95: 204-207, 2000.
62. Rosen G: Preoperative (neoadjuvant) chemotherapy for osteogenic sarcoma: A ten year experience. Orthopedics 8:659-664, 1985.
63. Rosen G, Caparros B, Huvos AG, et al: Preoperative chemotherapy for osteogenic sarcoma: Selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 49:1221-1230, 1982.
64. Rosen G, Marcove RC, Caparros B, et al: Primary osteosarcoma: The rationale for preoperative chemotherapy and delayed surgery. Cancer 43:2163-2177, 1979.
65. Rosen G, Nirenberg A, Jurgens H, et al: Response of Primary Osteogenic Sarcoma to Single-agent Therapy with High Dose Methotrexate with Citrovorum Factor Rescue. In Nelson JD, Grassi C (eds). Current Chemotherapy and Infectious Disease: Proceedings of the 11th International Congress of Chemotherapy and the 19th Interscience Conference on Antimicrobial Agents and Chemotherapy. Vol 2. Washington, DC, American Society for Microbiology 1633-1635, 1980.
66. Rosen G, Tan C, Sanmaneechai A, et al: The rationale for multiple drug chemotherapy in the treatment of osteogenic sarcoma. Cancer 35:936-945, 1975.
67. Schima W, Amann G, Stiglbauer R, et al: Preoperative staging of osteosarcoma: Efficacy of MR imaging in detecting joint involvement. AJR Am J Roentgenol 163:1171-1175, 1994.
68. Serra M, Scotlandi K, Reverter-Branchat G, et al: Value of P-glycoprotein and clinicopathologic factors as the basis for new treatment strategies in high-grade osteosarcoma of the extremities. J Clin Oncol 21:536-542, 2003.
69. Shin KH, Rougraff BT, Simon MA: Oncologic outcomes of primary bone sarcomas of the pelvis. Clin Orthop 304:207-217, 1994.
70. Smeland S, Muller C, Alvegard TA, et al: Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: Prognostic factors for outcome and role of replacement salvage chemotherapy for poor histological responders. Eur J Cancer 39:488-494, 2003.
71. Stein I, Beller ML: Osteogenic sarcoma of bone. Clin Orthop 7: 41-46, 1956.
72. Stine KC, Saylors RL, Saccente S, Becton DL: Long-term survival in osteoarcoma patients following retinoblastoma using doxorubicin, cisplatin, and methotrexate. Med Pediatr Oncol 41:77-78, 2003.
73. Sulzbacher I, Birner P: Tirieb, Pichlbauer E, Lang S: The expression of bone morphogenetic proteins in osteosarcoma and its relevance as a prognostic measure. J Clin Pathol 55:381-385, 2002.
74. Sutow WW: Multidrug chemotherapy in osteosarcoma. Clin Orthop 153:67-72, 1981.
75. Sweetnam R: Osteosarcoma. J Bone Joint Surg 52B:783-784, 1970.
76. Szendroi M, Papai Z, Koos R, Illes T: Limb-saving surgery, survival and prognostic factors for osteosarcoma: The Hungarian experience. J Surg Oncol 73:67-94, 2000.
77. Thompson Jr RC, Cheng EY, Clohisy DR, et al: Results of treatment for metastatic osteosarcoma with neoadjuvant chemotherapy and surgery. Clin Orthop 397:240-247, 2002.
78. Veeth RP: IIB osteosarcoma: Current management, local control and survival statistics: The Netherlands. Clin Orthop 270:67-71, 1991.
79. Weeden S, Grimer RJ, Cannon SR, Taminiau AH, Uscinska BM: European Osteosarcoma Intergroup: The effect of local recurrence on survival in resected osteosarcoma. Eur J Cancer 37:39-46, 2001.
80. Weinfeld MS, Dudley HR: Osteogenic sarcoma: A followup study of the ninety-four cases observed at the Massachusetts General Hospital from 1920 to 1960. J Bone Joint Surg 44A:269-276, 1962.
81. Yokoyama R, Schneider-Stock R, Radig K, Wex T, Roessner A: Clinicopathologic implications of MDM2, p53 and K-ras alterations in osteosarcomas: MDM2 amplification and p53 mutations found in progressive tumors. Pathol Res Pract 194:615-621, 1998.
82. Zhou H, Randall RL, Brothman AR, et al: Her-2/neu expression in osteosarcoma increases risk of lung metastasis and can be associated with gene amplification. J Pediatr Hematol Oncol 25:27-32, 2003.